Task 1 two-way ANCOVA significant results. by Mucahit Gemici (21519313)

Task 2 one-way ANCOVA significant results. by Mucahit Gemici (21519313)

Significant associations in GWAS. by Dai Nogimura (21445649)

Subjects:

eQTL analysis of significant SNPs. by Dai Nogimura (21445649)

Subjects:

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Significant Wilcoxon test results of the Task 1 Nasa TLX data, differences between feedback ON and OFF. by Mucahit Gemici (21519313)

Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

Data Sheet 1_Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.docx by Aida López Ruiz (21611177)

“…To address this need, in this work, we utilized a bioinspired, scalable, tunable platform to direct T-cell activation and decrease exhaustion during CAR T production.…”

Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx by Jianhong Ren (2186293)

“…Yield of intercropped XY per meter row was 13.3% and 17.0% higher than sole XY in two years; however, yield of intercropped ZD in IND and IHD was 16.7% and 25.3% lower than sole ZD in this study, respectively. Compared with IND, IHD did not significantly improve the population yield. …”

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects:

Ranking of factors in order of importance as reported by survey respondents regarding the difficulty in accessing the lower uterine segment (A), complicated fetal extraction in ces... by María Jesús Cancelo Hidalgo (12154030)

Subjects:

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

This is the data set that we used to reach the conclusions drawn in the manuscript with related metadata and methods. by Farayi Kaseke (19560197)

Subjects:

Group control-after intervention. by Nan Tang (642590)

Subjects:

Group SFA-before intervention. by Nan Tang (642590)

Subjects: